New drug development 100O RESULTS OF A RANDOMIZED PHASE 2 STUDY OF PD 0332991, A CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITOR, IN COMBINATION WITH LETROZOLE VS LETROZOLE ALONE FOR FIRST-LINE TREATMENT OF ER + /HER2- ADVANCED BREAST CANCER
نویسندگان
چکیده
R.S. Finn1, J.P. Crown2, K. Boer3, I. Lang4, R.J. Parikh5, A. Breazna6, S.N. Ho7, S.T. Kim8, S. Randolph8, D.J. Slamon1 Department of Hematology and Oncology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA, Irish Cooperative Oncology Research Group, St. Vincent’s Hospital, Dublin, IRELAND, Onkologia, 3Szent Margit Korhaz, Budapest, HUNGARY, Department of Medical-oncology and Clinical Pharmacology “b”, National Institute of Oncology, Budapest, HUNGARY, Sienna Location, Comprehensive Cancer Centers of Nevada, Department of Oncology, Clinical Development, Pfizer Oncology, New York, NY, UNITED STATES OF AMERICA, Translational Oncology, Pfizer Oncology, La Jolla, CA,UNITED STATES OF AMERICA, Clinical Development, Oncology Business Unit, Pfizer Oncology, La Jolla, CA, UNITED STATES OF AMERICA
منابع مشابه
Neutropenia due to palbociclib: A word of caution?
REFERENCES 1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin‐dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427‐38. 2. Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone‐receptor‐positive advanced breast cancer. N Engl J Med 2015;373:1672‐3. 3. Finn RS, ...
متن کاملNew directions in improving response to endocrine therapy cancer.
S6-01. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive ...
متن کاملDevelopment of cell-cycle checkpoint therapy for solid tumors.
Cellular proliferation is tightly controlled by several cell-cycle checkpoint proteins. In cancer, the genes encoding these proteins are often disrupted and cause unrestrained cancer growth. The proteins are over-expressed in many malignancies; thus, they are potential targets for anti-cancer therapies. These proteins include cyclin-dependent kinase, checkpoint kinase, WEE1 kinase, aurora kinas...
متن کاملNew horizon in breast cancer therapy: highlights from the European Society for Medical Oncology
This podcast presents an overview of new therapies on the horizon for breast cancer in terms of data presented at the European Society for Medical Oncology Congress, American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium. In the adjuvant setting, results from the Microarray In Node negative Disease may Avoid ChemoTherapy (MINDACT) trial, which evaluated genomic versus...
متن کاملProfile of palbociclib in the treatment of metastatic breast cancer
Breast cancer is the most common cancer diagnosed in women. Each year, thousands die either because of disease progression or failure of treatment. Breast cancer is classified into different subtypes based on the molecular expression of estrogen receptor (ER), progesterone receptor, and/or human epidermal growth factor receptor 2 (HER2). These receptors represent important therapeutic targets e...
متن کامل